Conference Call Scheduled for March 3, 2025, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report fourth quarter and full year 2024 financial results on March 3, 2025, after the U.S. financial markets close. ADMA’s management team will host a live conferen ...

Company Performance - Adma Biologics (ADMA) closed at $16.07, down 0.62% from the previous trading session, underperforming the S&P 500's gain of 0.24% [1] - Over the past month, shares of Adma Biologics have gained 0.06%, lagging behind the Medical sector's gain of 3.63% and the S&P 500's gain of 2.37% [1] Financial Projections - The upcoming earnings per share (EPS) for Adma Biologics is projected to be $0.15, representing a 275% increase from the same quarter last year [2] - Revenue is estimated to be $112.2 million, reflecting a 51.83% increase from the prior-year quarter [2] Analyst Forecasts - Recent revisions to analyst forecasts for Adma Biologics are important as they indicate evolving short-term business trends, with positive revisions suggesting optimism about the company's outlook [3] - The Zacks Rank system, which incorporates estimate changes, aims to provide actionable ratings based on these revisions [4] Zacks Rank and Valuation - Adma Biologics currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate moving 2.24% higher over the past month [5] - The company has a Forward P/E ratio of 23.61, which is a premium compared to the industry average Forward P/E of 22.58 [6] Industry Context - The Medical - Biomedical and Genetics industry, which includes Adma Biologics, holds a Zacks Industry Rank of 68, placing it in the top 28% of over 250 industries [6] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks, indicating that top-rated industries outperform lower-rated ones by a factor of 2 to 1 [7]

Pharmaceutical concern ADMA Biologics Inc (NASDAQ:ADMA) has been consolidating above familiar pressure at the $16 region since mid-January. A breakout could be on the way, however, as the stock just came into contact with a historically bullish trendline. Per Schaeffer's Senior Quantitative Analyst Rocky White, ADMA has come within striking distance of its 200-day moving average after a lengthy period above it (defined by White as 80% of the time over the past two months and 8 of the last 10 trading days). ...

ADMA Biologics’ (ADMA) shares have lost 8.9% in a month against the industry’s growth of 6.6%.The company has put up a phenomenal performance in 2024 and hit a 52-week high of $23.64 on Nov. 11.Last month, ADMA reported preliminary revenues for 2024 and provided a business update. On a preliminary basis, total revenues in 2024 are estimated to be in the $417-$425 million range (exceeding previous guidance of $415 Million). Total cash holdings at the end of 2024 grew to more than $100 million.ADMA Underperfo ...

Adma Biologics (ADMA) ended the recent trading session at $16.92, demonstrating a +0.3% swing from the preceding day's closing price. The stock lagged the S&P 500's daily gain of 0.36%. Meanwhile, the Dow experienced a drop of 0.28%, and the technology-dominated Nasdaq saw an increase of 0.51%.Coming into today, shares of the infectious disease drug developer had lost 9.11% in the past month. In that same time, the Medical sector gained 5.92%, while the S&P 500 gained 2.11%.Investors will be eagerly watchin ...

This is my first cover of ADMA Biologics (NASDAQ: ADMA ). In the article, I will describe ADMA Biologics' business areas and my opinion on how they will affect the company's future. I will try to compare ADMA's product to the competition andI first entered investing in 2016 as an individual value investor. In 2022, I established the investment firm Libra Capital. I mostly write articles as part of my deep research into a company before I make an investment, whether long or short. For me, a ''hold'' article ...

Core Viewpoint - Adma Biologics is experiencing fluctuations in stock performance, with a recent increase in share price, but a decline over the past month, while upcoming financial results are anticipated to show significant year-over-year growth in earnings and revenue [1][2]. Group 1: Stock Performance - Adma Biologics shares closed at $16.47, reflecting a +1.92% change from the previous day, outperforming the S&P 500's gain of 0.61% [1] - Over the past month, shares have decreased by 7.18%, underperforming both the Medical sector's gain of 1.64% and the S&P 500's gain of 2.08% [1] Group 2: Financial Expectations - Analysts expect Adma Biologics to report earnings of $0.15 per share, indicating a year-over-year growth of 275% [2] - Revenue is forecasted to be $112.2 million, representing a 51.83% increase compared to the same quarter last year [2] Group 3: Analyst Projections - Recent shifts in analyst projections for Adma Biologics are important for investors, as positive changes indicate optimism regarding the company's business and profitability [3] - The Zacks Rank system, which incorporates these estimate changes, suggests a correlation between estimate adjustments and stock price performance [4] Group 4: Zacks Rank and Valuation - Adma Biologics currently holds a Zacks Rank of 3 (Hold), with a consensus EPS projection that has decreased by 11.61% in the past 30 days [5] - The company has a Forward P/E ratio of 23.59, which is higher than the industry average of 21.95, indicating it is trading at a premium [6] Group 5: Industry Context - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, has a Zacks Industry Rank of 72, placing it in the top 29% of over 250 industries [6] - The Zacks Industry Rank assesses the strength of industry groups, with top-rated industries outperforming lower-rated ones by a factor of 2 to 1 [7]

Core Insights - ADMA Biologics, Inc. reported preliminary unaudited total revenue for FY 2024 between $417 million and $425 million, exceeding previous guidance of $415 million [1] - The company’s total cash holdings at year-end 2024 grew to over $100 million, reflecting a net cash surplus despite discharging $30 million of debt during Q4 2024 [1] - ADMA anticipates generating over $1 billion in total annual revenue prior to 2030, more than doubling the current 2025 revenue forecast [1][7] Financial Performance - FY 2025 and 2026 total revenue guidance is expected to exceed $485 million and $600 million, respectively [3][7] - FY 2025 and 2026 net income is expected to exceed $170 million and $230 million, respectively [3][7] - FY 2025 and 2026 adjusted EBITDA is expected to exceed $220 million and $300 million, respectively [3][7] Business Updates - Newly executed long-term high-titer plasma supply contracts are expected to support ASCENIV revenue growth through the late 2030s [2][7] - A Prior Approval Supplement (PAS) has been submitted to the FDA for an innovative yield enhancement production process, with potential regulatory approval anticipated by mid-2025 [2][7] - The innovative process is expected to increase Immunoglobulin (IG) yields by approximately 20%, driving revenue and earnings increases starting later in 2025 [2][7] Strategic Positioning - ADMA has solidified high-titer plasma supply on a long-term basis, increasing access to raw material plasma from approximately 250 collection centers, a five-fold increase in total collection capacity [7] - The company is focused on optimizing its balance sheet, having generated approximately $45 million in operating cash flow in Q4 2024, leading to a net cash surplus relative to its outstanding debt [7] - ADMA is leveraging its robust intellectual property estate and innovative R&D engine, with potential upside from its lead R&D pipeline program, SG-001, targeting S. pneumonia [7]

Core Viewpoint - ADMA Biologics has experienced a significant stock price increase of 275.7% over the past year, contrasting with a 14.3% decline in the industry, driven by strong quarterly performance and raised guidance [1][3]. Company Performance - ADMA Biologics specializes in plasma-derived biologics for treating immune deficiencies and preventing certain infectious diseases, with three FDA-approved products: Bivigam, Asceniv, and Nabi-HB [4]. - The lead product, Asceniv, is a plasma-derived IVIG that contains polyclonal antibodies, indicated for treating primary immunodeficiency disease (PIDD) in adults and adolescents [5]. Financial Highlights - Total revenues in the third quarter increased by 78%, attributed to higher sales of Asceniv and third-party plasma sales from ADMA's BioCenters [6]. - ADMA has raised its revenue guidance for 2024 to over $415 million and for 2025 to over $465 million, with net income projections exceeding $120 million in 2024 and $165 million in 2025 [9]. Product Development - ADMA is conducting a pediatric study for Asceniv, which may lead to label expansion to include pediatric patients, with a potential application filing expected in the coming quarters [7][8]. Margin and Valuation - The higher-margin product portfolio now constitutes over 50% of total revenues, with plans to increase Asceniv's supply, potentially enhancing margins and earnings growth [10]. - ADMA's shares currently trade at a price/sales ratio of 8.86x forward sales, significantly higher than the industry average of 1.69x [11]. Market Outlook - The market for plasma-derived products has substantial growth potential, particularly in the underserved immune-compromised patient population [14].

Company Overview - ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3] - The company currently manufactures and markets three FDA-approved plasma-derived biologics: BIVIGAM, ASCENIV™, and NABI-HB, targeting immune deficiencies and prevention of certain infectious diseases [3] - ADMA operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and also runs ADMA BioCenters, an FDA-approved source plasma collector [3] Upcoming Events - Company management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California, from January 13-16, 2025, with ADMA's presentation scheduled for January 13, 2025, at 10:30 a.m. PT [1] - A live audio webcast of the presentation will be available on the company's investor website, with an archived version accessible approximately two hours after the event [2]